The Immediate Financial Impact of Using PainChek

The RoI value to a care home

Authored by independent consultant, Daniel Casson, this report evaluates the short term financial return on investment of PainChek within residential and nursing homes in the UK. 

This report includes:

  • How PainChek supports financial and operational resilience for providers 
  • How PainChek protects occupancy levels
  • Real world data and insights from UK based care providers
Casson Consulting report - Digital FINALFront coverPNG

Download the ROI Report

Discover how PainChek delivers measurable financial returns for care providers.

PainChek® meets regulatory standards for use in Australia, New Zealand, Canada, Singapore, Malaysia, the United Kingdom, the European Union, and specifically, a United States FDA De Novo request application is currently underway for PainChek® Adult. The tool is included in the Australian Register of Therapeutic Goods (ARTG) under ARTG number 302794.

PainChek® is a registered trade mark of PainChek in Australia, the United Kingdom, the European Union, and a trade mark in other jurisdictions.